Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-17T02:24:50.510Z Has data issue: false hasContentIssue false
  • English
  • Français

Cognitive symptoms in mayor depression: A study with vortioxetina

Published online by Cambridge University Press:  23 March 2020

O. Porta Olivares ,
M. Juncal Ruiz ,
B. Fernández Abascal Puente ,
M. Gómez Revuelta ,
M. Pérez Herrera ,
G. Pardo de Santayana Jenaro ,
L. Sánchez Blanco ,
A.B. Pérez Santos ,
F. Arnaiz de las Revillas Almajano  and
R. Martín Gutiérrez
...Show all authors
O. Porta Olivares
Affiliation:
Hospital Universitario Marques De Valdecilla, General Psychiatry, Santander, Spain
M. Juncal Ruiz
Affiliation:
Hospital Universitario Marques De Valdecilla, General Psychiatry, Santander, Spain
B. Fernández Abascal Puente
Affiliation:
Hospital Universitario Marques De Valdecilla, General Psychiatry, Santander, Spain
M. Gómez Revuelta
Affiliation:
Hospital Universitario De Alava, General Psychiatry, Vitoria-gasteiz, Spain
M. Pérez Herrera
Affiliation:
Hospital Universitario Marques De Valdecilla, General Psychiatry, Santander, Spain
G. Pardo de Santayana Jenaro
Affiliation:
Hospital Universitario Marques De Valdecilla, General Psychiatry, Santander, Spain
L. Sánchez Blanco
Affiliation:
Hospital Universitario Marques De Valdecilla, General Psychiatry, Santander, Spain
A.B. Pérez Santos
Affiliation:
Hospital Universitario Marques De Valdecilla, General Medicine, Santander, Spain
F. Arnaiz de las Revillas Almajano
Affiliation:
Hospital Universitario Marques De Valdecilla, General Medicine, Santander, Spain
R. Martín Gutiérrez
Affiliation:
Hospital Universitario Marques De Valdecilla, General Psychiatry, Santander, Spain
R. Landera Rodríguez
Affiliation:
Hospital Universitario Marques De Valdecilla, General Psychiatry, Santander, Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

The major depression is associated with decreased cognitive functions in a range of areas, including attention, memory and executive functions. The cognitive symptoms of depression can have a profound effect on the ability of patients to keep out the tasks of daily living, and are significant factors that affect the ability to function both interpersonal and occupational level.

Aims

Vortioxetina have a multimodal action acting on various serotonin receptors in addition to inhibiting serotonin reuptake. Vortioxetina, is a new therapeutic tool seems to have shown efficacy in the treatment of cognitive symptoms of depression.

Methods

To evaluate this action we have evaluated the cognitive decline in patients with major depression before receiving treatment vortioxetina (whether state or not previously treated with other antidepressants) and at 2, 6 and 12 months after starting treatment with the drug. For that, we’ve used the Verbal Hearing Test King (RAVLT), which evaluates the auditory verbal short-term memory, the learning rate, the retention of information, and the differences between learning and recovery, and testing Digit substitution by symbols (DSST) that perform quick detection of brain dysfunctions by a conventional task.

Results

The results of this study are still under analysis.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
e-Poster viewing: Cultural psychiatry
Information
European Psychiatry , Volume 41 , Issue S1: Abstract of the 25th European Congress of Psychiatry , April 2017 , pp. S538
Copyright
Copyright © European Psychiatric Association 2017
Submit a response

Comments

No Comments have been published for this article.